These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 32461076)

  • 1. The effect of reduced gastric acid secretion on the gastrointestinal disposition of a ritonavir amorphous solid dispersion in fasted healthy volunteers: an in vivo - in vitro investigation.
    Van Den Abeele J; Kostantini C; Barker R; Kourentas A; Mann JC; Vertzoni M; Beato S; Reppas C; Tack J; Augustijns P
    Eur J Pharm Sci; 2020 Aug; 151():105377. PubMed ID: 32461076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biopharmaceutic
    Arora S; Pansari A; Kilford P; Jamei M; Gardner I; Turner DB
    Mol Pharm; 2020 Jul; 17(7):2329-2344. PubMed ID: 32427480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. On the usefulness of four in vitro methods in assessing the intraluminal performance of poorly soluble, ionisable compounds in the fasted state.
    O'Dwyer PJ; Box KJ; Imanidis G; Vertzoni M; Reppas C
    Eur J Pharm Sci; 2022 Jan; 168():106034. PubMed ID: 34628003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gastrointestinal and Systemic Disposition of Diclofenac under Fasted and Fed State Conditions Supporting the Evaluation of in Vitro Predictive Tools.
    Van Den Abeele J; Schilderink R; Schneider F; Mols R; Minekus M; Weitschies W; Brouwers J; Tack J; Augustijns P
    Mol Pharm; 2017 Dec; 14(12):4220-4232. PubMed ID: 28621952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro dissolution methodology, mini-Gastrointestinal Simulator (mGIS), predicts better in vivo dissolution of a weak base drug, dasatinib.
    Tsume Y; Takeuchi S; Matsui K; Amidon GE; Amidon GL
    Eur J Pharm Sci; 2015 Aug; 76():203-12. PubMed ID: 25978875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insights into the Dissolution Mechanism of Ritonavir-Copovidone Amorphous Solid Dispersions: Importance of Congruent Release for Enhanced Performance.
    Indulkar AS; Lou X; Zhang GGZ; Taylor LS
    Mol Pharm; 2019 Mar; 16(3):1327-1339. PubMed ID: 30669846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring the impact of real-life dosing conditions on intraluminal and systemic concentrations of atazanavir in parallel with gastric motility recording in healthy subjects.
    Hens B; Masuy I; Deloose E; Mols R; Tack J; Augustijns P
    Eur J Pharm Biopharm; 2020 May; 150():66-76. PubMed ID: 32113916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gastrointestinal dissolution, supersaturation and precipitation of the weak base indinavir in healthy volunteers.
    Rubbens J; Brouwers J; Tack J; Augustijns P
    Eur J Pharm Biopharm; 2016 Dec; 109():122-129. PubMed ID: 27693678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ritonavir-PEG 8000 amorphous solid dispersions: in vitro and in vivo evaluations.
    Law D; Schmitt EA; Marsh KC; Everitt EA; Wang W; Fort JJ; Krill SL; Qiu Y
    J Pharm Sci; 2004 Mar; 93(3):563-70. PubMed ID: 14762895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biorelevant Two-Stage In Vitro Testing for rDCS Classification and in PBPK Modeling-Case Example Ritonavir.
    Fiolka T; Van Den Abeele J; Augustijns P; Arora S; Dressman J
    J Pharm Sci; 2020 Aug; 109(8):2512-2526. PubMed ID: 32387425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening for Differences in Early Exposure in the Fasted State with in Vitro Methodologies can be Challenging: Experience with the BioGIT System.
    Kostantini C; Spilioti E; Bevernage J; Ceulemans J; Hansmann S; Hellemans K; Jede C; Kourentas A; Reggane M; Shah L; Wagner C; Vertzoni M; Reppas C
    J Pharm Sci; 2023 Aug; 112(8):2240-2248. PubMed ID: 36918113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of biorelevant in vitro assays for the assessment and optimization of ASD-based formulations for pediatric patients.
    Niessen J; López Mármol Á; Ismail R; Schiele JT; Rau K; Wahl A; Sauer K; Heinzerling O; Breitkreutz J; Koziolek M
    Eur J Pharm Biopharm; 2023 Apr; 185():13-27. PubMed ID: 36813089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of reduced gastric acid secretion on dissolution of salts of weak bases in the fasted upper gastrointestinal lumen: Data in biorelevant media and in human aspirates.
    Litou C; Vertzoni M; Xu W; Kesisoglou F; Reppas C
    Eur J Pharm Biopharm; 2017 Jun; 115():94-101. PubMed ID: 28214603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gastric and Duodenal Diclofenac Concentrations in Healthy Volunteers after Intake of the FDA Standard Meal: In Vivo Observations and in Vitro Explorations.
    Rubbens J; Brouwers J; Tack J; Augustijns P
    Mol Pharm; 2019 Feb; 16(2):573-582. PubMed ID: 30571131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of the amorphous solid dispersion erosion behavior following a novel small-scale predictive approach.
    Bochmann ES; Steidel A; Rosenblatt KM; Gessner D; Liepold B
    Eur J Pharm Sci; 2021 Mar; 158():105682. PubMed ID: 33347981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of a Weakly Acidic Amorphous Solid Dispersion of the Weak Base Ritonavir with Equivalent In Vitro and In Vivo Performance to Norvir Tablet.
    Ellenberger DJ; Miller DA; Kucera SU; Williams RO
    AAPS PharmSciTech; 2018 Jul; 19(5):1985-1997. PubMed ID: 29869311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aqueous Dissolution and Dispersion Behavior of Polyvinylpyrrolidone Vinyl Acetate-based Amorphous Solid Dispersion of Ritonavir Prepared by Hot-Melt Extrusion with and without Added Surfactants.
    Siriwannakij N; Heimbach T; Serajuddin ATM
    J Pharm Sci; 2021 Apr; 110(4):1480-1494. PubMed ID: 32827493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring the Effect of Esomeprazole on Gastric and Duodenal Fluid Volumes and Absorption of Ritonavir.
    de Waal T; Rubbens J; Grimm M; Vandecaveye V; Tack J; Weitschies W; Brouwers J; Augustijns P
    Pharmaceutics; 2020 Jul; 12(7):. PubMed ID: 32708859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In Vitro Lipolysis Model to Predict Food Effect of Poorly Water-Soluble Drugs Itraconazole, Rivaroxaban, and Ritonavir.
    Patel RP; Cristofoletti R; Wu F; Shoyaib AA; Polli JE
    J Pharm Sci; 2024 Aug; 113(8):2361-2373. PubMed ID: 38614321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase Behavior of Ritonavir Amorphous Solid Dispersions during Hydration and Dissolution.
    Purohit HS; Taylor LS
    Pharm Res; 2017 Dec; 34(12):2842-2861. PubMed ID: 28956218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.